Physician profile
Daniel J Ra
NPI 1386881928
$2,145.55
in general payments reported to CMS, 2019-2025
16 companies · $429 in 2025
The $429 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $447 · 2020: $132 · 2021: $442 · 2022: $297 · 2023: $98.70 · 2024: $300 · 2025: $429.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $803 · Education: $24.61.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $802.76 |
| Education | $24.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vifor Pharma, INC. | $524.90 | 2019-2025 | Veltassa |
| Bayer Healthcare Pharmaceuticals INC. | $296.77 | 2021-2025 | |
| Astrazeneca Pharmaceuticals Lp | $277.25 | 2019-2025 | Farxiga |
| Amgen INC. | $162.42 | 2019-2025 | Krystexxa |
| Calliditas Therapeutics US INC. | $150.65 | 2022-2025 | Tarpeyo |
| Ardelyx, INC. | $142.33 | 2024-2025 | Ibsrela |
| Abbott Laboratories | $130.18 | 2019 | |
| Akebia Therapeutics INC | $109.71 | 2019-2024 | Vafseo, Auryxia |
| Genzyme Corporation | $99.13 | 2019 | |
| Opko Pharmaceuticals, LLC | $72.99 | 2020-2025 | Rayaldee |
| Otsuka America Pharmaceutical, INC. | $61.94 | 2019-2024 | Jynarque |
| Fresenius USA Marketing, INC. | $47.12 | 2019-2024 | Velphoro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.33 | 2025 | Jardiance |
| Scpharmaceuticals INC. | $17.67 | 2025 | |
| Novartis Pharmaceuticals Corporation | $17.10 | 2025 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $17.06 | 2025 | Ozempic |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Ra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.